Browse the evidence

The use of medications for obesity will likely require lifelong treatment.

Practitioners should prepare for long-term management strategies when prescribing obesity medications.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

Designer drugs using mono, dual, and triple agonists of GLP-1, GIP, and glucagon can promote weight loss without effort.

Practitioners may consider these drugs as potential options for patients struggling with obesity.

There are fundamental biological principles that raise questions about the therapies for obesity.

Practitioners should be aware of the complexities and potential limitations of obesity therapies.

Muscle tissue protein synthesis and breakdown rates range between 1% and 2% across the day in vivo in humans.

Understanding the turnover rates can help in designing effective training and nutrition strategies.

Human body weight is physiologically regulated and maintained within a relatively narrow range in most mammals, including humans.

Understanding body weight regulation can inform strategies for managing obesity.

Difficulties in achieving body weight loss and maintenance in obese subjects are partly due to physiological regulatory systems that resist weight loss.

Recognizing these physiological challenges can guide effective weight loss strategies.

Novel antidiabetic medications have demonstrated cardiovascular safety and benefits by reducing major adverse cardiac events, improving heart failure, and decreasing CVD-related mortality.

Practitioners should consider novel antidiabetic medications for patients with diabetes and coronary artery disease to improve cardiovascular outcomes.

Metformin shows CVD protective properties for DM-induced atherosclerotic and macrovascular complications.

Metformin should be considered as a first-line treatment for type 2 diabetes to protect against cardiovascular complications.

Insulin monotherapy for T2DM treatment increases the risk of major CV events and deaths from HF compared to metformin.

Practitioners should be cautious when prescribing insulin monotherapy for type 2 diabetes due to increased cardiovascular risks.

Post-exercise changes in proteins reflective of protein synthesis were similar between groups, though some mRNA exhibited exercise order-dependent responses.

Understanding the molecular responses can help tailor exercise programs for optimal protein synthesis.

Steep weight loss postintervention was associated with increased risk of mortality.

Healthcare providers should be cautious of rapid weight loss in older patients with diabetes.

Obesity is a global epidemic and a significant public health challenge.

Recognize obesity as a critical issue in public health.

Current anti-obesity medications (AOMs) include gastrointestinal lipase inhibitors, nutrient-stimulated hormone-based therapies, and emerging multi-receptor agonists.

Consider these AOMs in obesity treatment strategies.

Obesity promotes the onset of atrial fibrillation (AF) through several pathways.

Understanding these pathways can help in developing targeted interventions for AF in obese patients.

Gastrointestinal tract adverse events were reported by 63.4% of participants on semaglutide.

Practitioners should monitor for gastrointestinal side effects in patients taking semaglutide.

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

GLP-1RA prescriptions significantly increased across all BMI categories among youth and adults with type 1 diabetes over the last 15 years.

Clinicians should consider the increasing use of GLP-1RAs in managing obesity in T1D patients.

Advancements in laparoscopic surgical technique have improved the safety and efficacy of bariatric metabolic surgery.

Surgeons should adopt new laparoscopic techniques to enhance patient outcomes in bariatric surgery.

Patients who received the fluid-filled IGB were more likely to require urgent evaluation or treatment compared to those treated with the gas-filled IGB.

Clinicians should be aware of the higher likelihood of complications with the fluid-filled IGB.

Recent insights into pathophysiological mechanisms suggest that OSA may be divided into distinct subgroups.

Understanding the subgroups in OSA may lead to more targeted treatments.